Drugs / autologous skin sheet graft
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01545323 | Apr 2014 → Apr 2018 | Netherton syndrome | Great Ormond Street Hospital for Children NHS Foundation Trust | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous skin sheet graft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01545323 ↗ |
| Action | Restore | “The investigators have used a disabled virus (vector) to carry a functional copy of the SPINK5 gene into skin stem cells.” NCT01545323 ↗ |
| Route | Other | “autologous epidermal sheets generated from ex vivo gene-corrected keratinocyte stem cells, which will be grafted onto patients with mutation-proven NS” PMID 24329107 ↗ Dec 2013 |
| Target | SPINK5 | “A SIN-lentiviral vector encoding the codon-optimized SPINK5 gene under the control of a 572 bp element derived from the human involucrin promoter can confer...” PMID 24329107 ↗ Dec 2013 |